Ascendis Pharma A/s Share Price: ASND (Ascendis Pharma A/s) Stock Price Today & Updates | INDmoney

Question 1

What is Ascendis Pharma A/s share price today?

Accepted Answer

Ascendis Pharma A/s (ASND) share price today is {{live_price}}.

Question 2

Can Indians buy Ascendis Pharma A/s shares?

Accepted Answer

Yes, Indians can invest in the Ascendis Pharma A/s (ASND) from India.

With INDmoney, you can buy Ascendis Pharma A/s at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Ascendis Pharma A/s at zero transaction cost.

Question 3

How can I buy Ascendis Pharma A/s shares from India?

Accepted Answer

It is very easy to buy Ascendis Pharma A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Question 4

Can Fractional shares of Ascendis Pharma A/s be purchased?

Accepted Answer

Yes, you can buy fractional shares of Ascendis Pharma A/s with INDmoney app.

Question 5

What are the documents required to start investing in Ascendis Pharma A/s stocks?

Accepted Answer

To start investing in Ascendis Pharma A/s, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

Question 6

What are today’s High and Low prices of Ascendis Pharma A/s

Accepted Answer

Today’s highest price of Ascendis Pharma A/s (ASND) is {{1_rba_end}}.

Today’s lowest price of Ascendis Pharma A/s (ASND) is {{1_rba_st}}.

Question 7

What is today's market capitalisation of Ascendis Pharma A/s

Accepted Answer

Today's market capitalisation of Ascendis Pharma A/s ASND is 7.7B

Question 8

What is the 52 Week High and Low Range of Ascendis Pharma A/s

Accepted Answer

52 Week High
{{rba_end}}
52 Week Low
{{rba_st}}

Question 9

How much percentage Ascendis Pharma A/s is down from its 52 Week High?

Accepted Answer

Ascendis Pharma A/s (ASND) share price is {{live_price}}. It is down by {{w52lu}}% from its 52 Week High price of {{rba_end}}.

Question 10

How much percentage Ascendis Pharma A/s is up from its 52 Week low?

Accepted Answer

Ascendis Pharma A/s (ASND) share price is {{live_price}}. It is up by {{w52hd}}% from its 52 Week Low price of {{rba_st}}.

Question 11

What are the historical returns of Ascendis Pharma A/s?

Accepted Answer

1 Month Returns
{{1mr}}%
3 Months Returns
{{3mr}}%
1 Year Returns
{{1yr}}%
5 Years Returns
{{5yr}}%

Question 12

Who is the Chief Executive Officer (CEO) of Ascendis Pharma A/s

Accepted Answer

Mr. Jan Moller Mikkelsen is the current Chief Executive Officer (CEO) of Ascendis Pharma A/s.

Period	Ascendis Pharma A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	-1.12%	6.5%	0.0%
6 Months	1.45%	7.1%	0.0%
1 Year	55.05%	9.8%	0.0%
3 Years	19.27%	14.2%	-20.2%

Market Capitalization	7.7B
Book Value	- $4.15
Earnings Per Share (EPS)	-9.66
Wall Street Target Price	181.98

Profit Margin	-152.44%
Operating Margin TTM	-51.25%

Return On Assets TTM	-25.51%
Return On Equity TTM	-818.43%

Revenue TTM	329.0M
Revenue Per Share TTM	5.83
Quarterly Revenue Growth YOY	185.5%
Gross Profit TTM	39.0M
EBITDA	-354.5M
Diluted Eps TTM	-9.66
Quarterly Earnings Growth YOY	0.0

Ascendis Pharma A/s (ASND)

Performance

Returns

Highlights

Analyst Recommendation

Analyst Forecast

Company Financials

Technicals Summary

Peers

Decreasing Revenue

Decreasing Net Profit

Vs NVO

Vs NVO

Institutional Holdings

Corporate Announcements

Ascendis Pharma A/s Earnings

Company Information

Discover More

FAQs

EPS Estimate Current Year	-5.68
EPS Estimate Next Year	-1.42
EPS Estimate Current Quarter	0.0
EPS Estimate Next Quarter	0.0

	FY18	Y/Y Change
Revenue	12.1M	↑ 591.57%
Net Income	-148.8M	↑ 5.0%
Net Profit Margin	-1.2K%	↑ 6868.31%

	FY19	Y/Y Change
Revenue	15.0M	↑ 26.41%
Net Income	-244.2M	↑ 67.58%
Net Profit Margin	-1.6K%	↓ 400.5%

	FY20	Y/Y Change
Revenue	8.6M	↓ 48.01%
Net Income	-515.3M	↑ 92.17%
Net Profit Margin	-6.0K%	↓ 4395.5%

	FY21	Y/Y Change
Revenue	8.8M	↑ 11.87%
Net Income	-434.4M	↓ 8.44%
Net Profit Margin	-4.9K%	↑ 1093.97%

	FY22	Y/Y Change
Revenue	54.8M	↑ 557.93%
Net Income	-624.7M	↑ 52.04%
Net Profit Margin	-1.1K%	↑ 3791.93%

	FY23	Y/Y Change
Revenue	266.7M	↑ 421.2%
Net Income	-481.4M	↓ 17.45%
Net Profit Margin	-180.51%	↑ 959.12%

	Q4 FY22	Q/Q Change
Revenue	24.5M	↑ 49.74%
Net Income	-222.2M	↑ 22.77%
Net Profit Margin	-905.91%	↑ 199.09%

	Q1 FY23	Q/Q Change
Revenue	36.6M	↑ 46.7%
Net Income	-121.0M	↓ 46.53%
Net Profit Margin	-330.21%	↑ 575.7%

	Q2 FY23	Q/Q Change
Revenue	51.7M	↑ 41.1%
Net Income	-132.5M	↑ 9.48%
Net Profit Margin	-256.23%	↑ 73.98%

	FY18	Y/Y Change
Total Assets	364.9M	↑ 51.18%
Total Liabilities	44.5M	↑ 63.74%

	FY19	Y/Y Change
Total Assets	758.1M	↑ 112.16%
Total Liabilities	89.2M	↑ 104.58%

	FY20	Y/Y Change
Total Assets	1.2B	↑ 44.78%
Total Liabilities	173.5M	↑ 77.2%

	FY21	Y/Y Change
Total Assets	1.2B	↑ 10.73%
Total Liabilities	228.0M	↑ 42.67%

	Q3 FY23	Q/Q Change
Revenue	48.0M	↑ 1.35%
Net Income	-162.2M	↑ 33.59%
Net Profit Margin	-337.73%	↓ 81.5%

	Q4 FY23	Q/Q Change
Revenue	137.7M	↑ 186.68%
Net Income	-86.9M	↓ 46.45%
Net Profit Margin	-63.09%	↑ 274.64%

	Q1 FY24	Q/Q Change
Revenue	103.5M	↓ 30.36%
Net Income	-141.5M	↑ 50.83%
Net Profit Margin	-136.65%	↓ 73.56%

	FY23	Y/Y Change
Total Assets	825.6M	↓ 24.24%
Total Liabilities	971.3M	↑ 17.53%

	Q2 FY23	Q/Q Change
Total Assets	898.9M	↓ 14.74%
Total Liabilities	828.1M	↓ 5.02%

	FY18	Y/Y Change
Operating Cash Flow	-158.8M	↑ 45.96%
Investing Cash Flow	-3.0M	↑ 181.4%
Financing Cash Flow	232.5M	↑ 62.98%

	FY19	Y/Y Change
Operating Cash Flow	-197.1M	↑ 26.75%
Investing Cash Flow	-5.8M	↑ 94.83%
Financing Cash Flow	552.9M	↑ 142.83%

	FY20	Y/Y Change
Operating Cash Flow	-334.0M	↑ 54.34%
Investing Cash Flow	-358.2M	↑ 5544.49%
Financing Cash Flow	741.3M	↑ 22.09%

	FY21	Y/Y Change
Operating Cash Flow	-473.0M	↑ 53.8%
Investing Cash Flow	-125.2M	↓ 62.03%
Financing Cash Flow	397.9M	↓ 41.69%

	FY22	Y/Y Change
Operating Cash Flow	-531.0M	↑ 18.69%
Investing Cash Flow	66.1M	↓ 155.83%
Financing Cash Flow	425.0M	↑ 12.92%

	Q4 FY22	Q/Q Change
Operating Cash Flow	-151.8M	↑ 43.36%
Investing Cash Flow	-853.8K	↓ 105.65%
Financing Cash Flow	1.4M	↓ 1875.0%

	Q1 FY23	Q/Q Change
Operating Cash Flow	-160.4M	↑ 3.78%
Investing Cash Flow	51.2M	↓ 5991.72%
Financing Cash Flow	-765.5K	↓ 152.04%

	Q2 FY23	Q/Q Change
Operating Cash Flow	-167.1M	↑ 4.14%
Investing Cash Flow	51.2M	↑ 0.0%
Financing Cash Flow	-2.5M	↑ 228.92%

	Q3 FY23	Q/Q Change
Operating Cash Flow	-124.7M	↓ 18.55%
Investing Cash Flow	22.2M	↓ 52.68%
Financing Cash Flow	143.4M	↓ 6308.66%

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Ascendis Pharma A/s	1.3%	1.45%	55.05%	19.27%	15.42%
Moderna, Inc.	-1.67%	18.26%	-0.21%	-64.15%	752.69%
Regeneron Pharmaceuticals, Inc.	-0.46%	13.21%	45.59%	84.19%	244.2%
Novo Nordisk A/s	-11.0%	18.31%	61.56%	186.46%	423.59%
Vertex Pharmaceuticals Incorporated	3.85%	14.43%	39.88%	147.45%	195.07%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Ascendis Pharma A/s	NA	NA	NA	-5.68	-8.18	-0.26	NA	-4.15
Moderna, Inc.	24.73	NA	0.0	-7.19	-0.38	-0.16	NA	33.47
Regeneron Pharmaceuticals, Inc.	31.35	31.35	1.46	44.44	0.15	0.08	NA	250.15
Novo Nordisk A/s	44.28	44.28	2.36	3.43	1.0	0.25	0.01	22.18
Vertex Pharmaceuticals Incorporated	31.85	31.85	0.53	16.98	0.24	0.13	NA	71.8

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Ascendis Pharma A/s	Buy	$7.7B	15.42%	NA	-152.44%
Moderna, Inc.	Buy	$45.3B	752.69%	24.73	-115.82%
Regeneron Pharmaceuticals, Inc.	Buy	$116.9B	244.2%	31.35	29.45%
Novo Nordisk A/s	Buy	$572.0B	423.59%	44.28	36.55%
Vertex Pharmaceuticals Incorporated	Buy	$126.7B	195.07%	31.85	39.46%

Organization	Ascendis Pharma A/s
Employees	879
CEO	Mr. Jan Moller Mikkelsen
Industry	Health Technology